10 Mar METEOROID MOGAD
Study Purpose
MOGAD is a rare condition that affects the central nervous system. The aim of this study is to test how effective and safe satralizumab is for treating adults and teenagers with MOGAD. The METEOROID study will look to see if satralizumab is safe and whether it works as treatment for MOGAD – for both preventing attacks and improving symptoms.
Recruitment
- Aged >12 years
- Diagnosis of MOG antibody disease
- Documented history of ≥2 MOGAD attacks
- Stable disease for 12 weeks before first dose
- No present or recurrent bacterial, viral, fungal, or other infection (excluding fungal infection of nail beds or dental caries)
- Able to tolerate MRI
- No history of cancer or other significant medical conditions
- Not pregnant or breast feeding
- Other criteria required to be reviewed
Recruitment Status
Open for enrollment